SCHEMBL24809752

SCHEMBL24809752

COc1nc(-c2ccccc2)cn1C(=O)NC1CCCC(F)(F)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 1/20 0.37
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
MAPK8 P45983 1/20 0.35
THRB P10828 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
SCN9A Q15858 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GAA P10253 1/20 0.34
HPGDS O60760 1/20 0.34
AKT1 P31749 1/20 0.34
AKT2 P31751 1/20 0.34
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.34
CETP P11597 1/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24809438 0.89 CNR1 (0.39) MAPTKDM4EHTTTDP1HPGDS
SCHEMBL24810590 0.84 KLK7 (0.44) MAPTKDM4EHTTMAPK8TDP1
SCHEMBL24811091 0.83 MAPK8 (0.38) HCRTR2MAPTMAPK8THRBSCN9A
SCHEMBL24809758 0.81 MAPK8 (0.36) HCRTR2MAPTMAPK8CETPALDH1A1
SCHEMBL24810591 0.71 EPHX2 (0.39)
SCHEMBL24809474 0.69 GBA1 (0.35) MAPTTDP1MEN1KMT2A
SCHEMBL24810582 0.68 CNR1 (0.39) SCN9A
SCHEMBL24810569 0.67 SMN1; SMN2 (0.42) MAPTHTTPOLBMEN1KMT2A
SCHEMBL29786319 0.65 PIM1 (0.34) MAPK8AKT1AKT2
SCHEMBL24809766 0.65 BCHE (0.34) MAPTKDM4EHPGDSPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed
EP-4031531-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
CN-114787135-A Substituted imidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 HCRTR2 2013/4885MAPT 217/4885KDM4E 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.